Surging demand, rapid product adoption, and geographic expansion position the company for revenue and margin growth well above current market expectations. Leadership in pediatric innovation and strengthening procedure volumes give the company enhanced pricing power and long-term earnings momentum.
Cyborg Score Rationale
Analyst price targets have been raised, with BTIG Research raising its target to $24.00 with a buy rating. Strong demand and geographic expansion position the company for above-market growth. However, the company is currently unprofitable and not forecast to become profitable over the next 3 years.
Top Insights
Q1 2025 revenue grew 17% to $52.4M and full-year revenue is projected at $236M-$242M (15-18% growth).
Strong international expansion and innovative product launches drive growth, but regulatory challenges and declining birth rates may limit long-term market potential.
Positive free cash flow is expected by Q4 2025 with U.S. revenue growth of 19% and international growth of 11%.
Institutional investors and hedge funds own 69.05% of the company's stock.
Named Competitors
SI-BONE Spine Implants — Orthopedic medical device manufacturer
Avanos Medical Devices — Medical device company serving orthopedic and surgical markets
Orthofix Products — Orthopedic medical device manufacturer
Recent Developments
(March 2026) BTIG Research raised price target to $24.00 with buy rating
(May 2025) Q1 2025 revenue beat analyst expectations at $52.4M with 17% YoY growth
(2025) FDA approvals received for new products and EU MDR approvals targeted for H2 2025
Open the full interactive OrthoPediatrics Corp report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.